Abstract:Abstract Background: Ovarian endometrioid carcinoma (OEC) is an uncommon, understudied histotype that is distinguished from other histotypes by unique genomic features and high hormone receptor expression. There is growing interest in the biological relevance of subtyping using immunohistochemistry (IHC). Methods: Women with primary invasive OEC diagnosed from 1989 to 2010 were retrospectively identified from the population-based Alberta Cancer Registry, Canada. Pathology slide review and IHC staining for Napsin A, TP53, and WT1 were used to reduce histologic misclassification, resulting in N=166 participants (low-stage N=138, high-stage N=28), excluding those who received neo-adjuvant chemotherapy. The following markers were stained and scored on tissue microarrays: TP53 (normal/abnormal), PMS2/MSH6 (mismatch repair proficient [MMRp]/deficient [MMRd]), PGR (loss/retained), and CTNNB1 (nuclear/cytoplasmic). Using a hierarchical decision tree by stage group (low/high), we categorized tumors as TP53 abnormal, MMRd, PGR loss, nuclear CTNNB1, and no specific immunohistochemical profile (NSIP). Distributions and five-year disease specific survival (DSS) was estimated for each group; hazard ratios (HRs) adjusted for age were estimated using Cox regression with NSIP as referent group. Results: Among low-stage cases, five-year survival was as follows: 80% for TP53 abnormal (N=10, 7%), 87% for MMRd (N=15, 11%), 80% for PGR loss (N=10, 7%), 98% for nuclear CTNNB1 (N=63, 46%), and 95% for NSIP group (N=40, 29%). Overall, IHC group was associated with DSS among low stage cases (LRT p-value=0.006), and the group with nuclear CTNNB1 had a small but statistically significant DSS advantage (HR=0.089, 95% CI 0.011-0.742, p=0.025). TP53 and PGR loss suggested shorter DSS than the referent NSIP group, but not statistically significantly so (HR=1.26 and 3.08, respectively). Among high-stage cases, five-year DSS was as follows: 57% for TP53 abnormal (N=7, 25%), 75% for MMRd (N=8, 29%), 33% for nuclear CTNNB1 (N=3, 11%), and 17% for NSIP (N=10, 36%). There were no high-stage cases in the PGR-loss group. Nuclear CTNNB1 group had a shorter DSS among high-stage cases, but this was not statistically significantly so (HR=1.16, p=0.85). Conclusion: Pending replication in additional datasets, results suggest that OEC cases in nuclear CTNNB1 or NSIP IHC groups may have a favorable prognosis in which de-escalation of therapy can be considered. In addition, abnormal TP53 and loss of PGR may identify a high-risk subset of low-stage OEC. Citation Format: Brooke Jorgensen, Stacey Winham, Julie Cunningham, Sebastian Armasu, Chen Wang, Hunter Atkinson, Bryan McCauley, Linda Kelemen, Martin Koebel, Ellen Goode. Towards a combined immunohistochemistry-based subtyping of ovarian endometrioid carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6499.

Differentiating primary and extragenital metastatic mucinous ovarian tumours: an algorithm combining PAX8 with tumour size and laterality.

and laterality algorithm combining PAX 8 with tumour size metastatic mucinous ovarian tumours : an Differentiating primary and extragenital and

Immunohistochemical expression of SATB2 and PAX8 in differentiating primary from metastatic ovarian mucinous neoplasms

Multiparametric MRI-based radiomics nomogram for differentiation of primary mucinous ovarian cancer from metastatic ovarian cancer

Distinguishing primary from secondary mucinous ovarian tumors: an algorithm using the novel marker DPEP1

Multimodal diagnostic strategies and precision medicine in mucinous ovarian carcinoma: a comprehensive approach

Utility of Combined Use of Imaging Features From Abdominopelvic CT and CA 125 to Identify Presence of CT Occult Peritoneal Metastases in Advanced Gastric Cancer

Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes.

Increased Diagnostic Accuracy of Adnexal Tumors with A Combination of Established Algorithms and Biomarkers

Evaluation of Selected MRI Parameters in the Differentiation of Mucinous Ovarian Carcinomas and Metastatic Ovarian Tumors

Establishing Molecular Subgroups of CD8+ T Cell-Associated Genes in the Ovarian Cancer Tumour Microenvironment and Predicting the Immunotherapy Response

Mucin-producing tumors of the ovary——preoperative differentiation between metastatic ovarian mucinous carcinoma and primary mucinous malignant tumors

Identifying mesonephric-like adenocarcinoma of the endometrium by combining SOX17 and PAX8 immunohistochemistry

SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas

Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses

HER2-low and Overexpression in Mucinous Ovarian Cancer: Analysis of ASCO/CAP and ToGA Immunohistochemical Scoring

Abstract 6499: Towards a combined immunohistochemistry-based subtyping of ovarian endometrioid carcinoma

Tumor Markers in Differential Diagnosis of Benign Ovarian Masses

Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry

The performance of Carbohydrate Antigen 125-Thomsen-nouveau and anti-Müllerian hormone combined with CA125, Human epididymis protein 4 and Risk of Malignancy Algorithm in diagnosis for patients with Epithelial ovarian cancer.

Determination of Tumor-infiltrating CD8+ Lymphocytes in Human Ovarian Cancer